#ATYR

1 week ago

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update aTyr Pharma (Nasdaq: ATYR) reported full-year 2025 results and a corporate update. The company ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments. R&D expense was $60.2 million and G&A expense was $17.6 million.The Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint, but 5.0 mg/kg efzofitimod showed clinical benefit on multiple secondary measures. A Type C meeting with the FDA is scheduled for mid-April 2026.

#ATYR aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

www.stocktitan.net/news/ATYR/a-tyr-pharma-a...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Levi & Korsinsky Urges aTyr Shareholders to Act Before December 2025 Deadline Levi & Korsinsky, LLP highlights an impending deadline for aTyr Pharma investors in a securities class action lawsuit, urging affected shareholders to act.

Levi & Korsinsky Urges aTyr Shareholders to Act Before December 2025 Deadline #United_States #New_York #Levi_&_Korsinsky #aTyr_Pharma #ATYR

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Investors in aTyr Pharma Inc. May Participate in Securities Fraud Lawsuit aTyr Pharma Inc. shareholders who have incurred losses can now join a class action lawsuit against the company, aiming for justice.

Investors in aTyr Pharma Inc. May Participate in Securities Fraud Lawsuit #United_States #Los_Angeles #Securities_Fraud #aTyr_Pharma #ATYR

0 0 0 0

Oninvest

@oninvest.bsky.social

4 months ago

After lead drug misses in late trial and stock craters, what's next for aTyr? – Oninvest Shares of aTyr Pharma, a biotech developer of therapies for pulmonary sarcoidosis, collapsed 83% in a single day on September 15 after the company’s lead drug failed in a pivotal phase III trial. The...

#ATYR plunged after its lead drug efzofitimod failed a Phase 3 trial in pulmonary sarcoidosis, showing no advantage over placebo. The setback leaves the company’s pipeline in question — read how it got here and what comes next: en.oninvest.com/article/afte...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Shareholders of aTyr Pharma, Inc. Encouraged to Join Class Action for Financial Recovery aTyr Pharma, Inc. shareholders who experienced losses are urged to take part in a class action lawsuit. The Gross Law Firm is leading the charge to recover losses for those affected.

Shareholders of aTyr Pharma, Inc. Encouraged to Join Class Action for Financial Recovery #USA #New_York #Gross_Law_Firm #aTyr_Pharma #ATYR

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Investor Alert: Pomerantz Law Firm Explores Legal Actions for aTyr Pharma Investors Pomerantz LLP is actively investigating potential securities fraud claims against aTyr Pharma, Inc. following disappointing trial results affecting investor confidence.

Investor Alert: Pomerantz Law Firm Explores Legal Actions for aTyr Pharma Investors #USA #New_York #Pomerantz_LLP #aTyr_Pharma #ATYR

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025 aTyr Pharma (NASDAQ:ATYR) presented additional findings from its Phase 3 EFZO-FIT™ study of efzofitimod in 268 pulmonary sarcoidosis patients at the ERS Congress 2025. While the study missed its primary endpoint regarding oral corticosteroid dose reduction, the 5.0 mg/kg efzofitimod treatment group showed significant improvements in multiple secondary endpoints including:The Fatigue Assessment Scale Total Score (p=0.0226) and King's Sarcoidosis Questionnaire-General Health score (p=0.0197) at week 48 versus placebo. The treatment also demonstrated improvements in KSQ-Lung score (p=0.0196), preservation of forced vital capacity, and maintained a well-tolerated safety profile.

#ATYR aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025

www.stocktitan.net/news/ATYR/a-tyr-pharma-p...

0 0 0 0

Oninvest

@oninvest.bsky.social

5 months ago

Shares of aTyr plunge 80%, analysts downgrade ratings as lead drug fails trial – Oninvest Freedom Broker and other analysts have downgraded aTyr Pharma, a small-cap developer of therapies for pulmonary sarcoidosis, after its lead drug candidate failed to show meaningful results over placeb...

💊 #ATyr plunged 83% after its lead drug efzofitimod failed to show meaningful benefit over placebo in a Phase 3 pulmonary sarcoidosis trial.

Freedom Broker, Cantor, and Leerink all downgraded #ATyr, citing lower approval odds and a weaker outlook. en.oninvest.com/article/shar...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Most Searched, Monday September 15, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Sept 15th - #RCEL #CLSK #IBRX #LDI #GPRO #GLUE #RZLV #ONDS #RIG #NAOV #HIVE #RXRX #NAKA #ATYR #WOLF #SBET #RR #QUBT #BITF #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis aTyr Pharma (Nasdaq: ATYR) announced topline results from its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. The study did not meet its primary endpoint of change in mean daily oral corticosteroid dose at week 48, with a reduction to 2.79 mg for efzofitimod vs 3.52 mg for placebo (p=0.3313).However, notable secondary findings included: 52.6% of patients on 5.0 mg/kg efzofitimod achieved complete steroid withdrawal vs 40.2% on placebo, improved King's Sarcoidosis Questionnaire-Lung scores (p=0.0479), and 29.5% of efzofitimod patients achieved both steroid withdrawal and lung score improvement vs 14.4% for placebo (p=0.0199). The drug was well-tolerated at both tested doses.The company plans to engage with the FDA to determine the path forward for efzofitimod in pulmonary sarcoidosis treatment.

#ATYR aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

www.stocktitan.net/news/ATYR/a-tyr-pharma-a...

0 0 0 0

Posts tagged #ATYR